Miguel Cordero-Coma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Miguel Cordero-Coma has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
Taygan Yilmaz
5 shared publicationsJosé M. García Ruiz de Morales
Unidad de Uveítis, Servicio de Inmunología, Complejo Asistencial Universitario de León, León, España; Instituto de Biomedicina, Universidad de León (IBIOMED), León, España
3 shared publicationsRaquel Salazar-Méndez
3 shared publicationsSara Calleja
Uveitis Unit, University Hospital of León, 24071 León, Spain ; Department of Immunology, University Hospital of León, 24071 León, Spain
3 shared publicationsA. Garrote Llordén
Complejo Asistencial Universitario de León, León, Spain
2 shared publications- Alfredo Adán
Department of Ophthalmology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain
2 shared publications
Latest Publications
- 1 March 2022
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología (English Edition)
- Vol. 97 (3) , 172-175
Ocular complications secondary to diode laser-assisted eyebrow epilation
- 1 March 2022
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología (English Edition)
- Vol. 97 (3) , 172-175
Ocular complications secondary to diode laser-assisted eyebrow epilation
- 1 March 2022
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 97 (3) , 172-175
Complicaciones oculares secundarias a depilación de las cejas con láser diodo
- 1 March 2022
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 97 (3) , 172-175
Complicaciones oculares secundarias a depilación de las cejas con láser diodo
- 19 March 2020
- Published by Elsevier in Medicina Clinica
- Vol. 155 (5) , 220.e1-220.e12
Documento de recomendaciones sobre el tratamiento con inmunodepresores de la uveítis no anterior, no infecciosa, no neoplásica
- 19 March 2020
- Published by Elsevier in Medicina Clinica
- Vol. 155 (5) , 220.e1-220.e12
Documento de recomendaciones sobre el tratamiento con inmunodepresores de la uveítis no anterior, no infecciosa, no neoplásica
- 1 August 2019
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 94 (8) , 413-416
Neurorretinitis estrellada idiopática de Leber: conflictos diagnósticos y terapéuticos
- 1 August 2019
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología
- Vol. 94 (8) , 413-416
Neurorretinitis estrellada idiopática de Leber: conflictos diagnósticos y terapéuticos
- 1 December 2017
- Published by Elsevier in Medicina Clinica
- Vol. 149 (12) , 552.e1-552.e12
Documento de recomendaciones de tratamiento de la uveítis anterior no infecciosa
- 1 December 2017
- Published by Elsevier in Medicina Clinica
- Vol. 149 (12) , 552.e1-552.e12
Documento de recomendaciones de tratamiento de la uveítis anterior no infecciosa
- Open Access
- 1 October 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (42) , e8045
Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis
To assess the efficacy and safety of immunomodulatory drugs in patients with noninfectious anterior uveitis (AU). Systematic review of studies were retrieved from Medline (1961 to March 2016), Embase (1961 to March 2016), and Cochrane Library (up to March 2016), and a complementary hand search was also performed. The selection criteria were as follows: (population) noninfectious AU patients, adults; (intervention) immunomodulatory drugs (any dose, regimen, route of administration, duration of treatment); (outcome) control of inflammation, steroid-sparing effect, AU flares, adverse events, and so on; (study design) systematic literature reviews, randomized controlled trials, and observational studies. The study quality was assessed using the Jadad scale and according to The Oxford Centre for Evidence-based Medicine (update 2009). We included 13 studies of moderate-poor quality, with a mean duration from 5 months to 20 years, and number of AU patients ranging from 9 to 274. Patient's demographic and clinical characteristics were very heterogeneous. In most cases, uveitis anatomic classification criteria and outcomes definitions were unclear. Some of the studies only included AU patients with a systemic disease associated, mostly spondyloarthritis, others, mixed populations (idiopathic and systemic disease associated patients), and in some articles this data is not described. We found that methotrexate, cyclosporine A, azathioprine, adalimumab, and golimumab might prevent AU flares, improve ocular inflammation and visual acuity, and decrease systemic steroids doses. Although there is a lack of robust evidence, methotrexate, cyclosporine A, azathioprine, adalimumab, and golimumab might be effective in AU patients.
- 1 October 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (42) , e8045
Open AccessEfficacy and safety of immunomodulatory drugs in patients with anterior uveitis
To assess the efficacy and safety of immunomodulatory drugs in patients with noninfectious anterior uveitis (AU). Systematic review of studies were retrieved from Medline (1961 to March 2016), Embase (1961 to March 2016), and Cochrane Library (up to March 2016), and a complementary hand search was also performed. The selection criteria were as follows: (population) noninfectious AU patients, adults; (intervention) immunomodulatory drugs (any dose, regimen, route of administration, duration of treatment); (outcome) control of inflammation, steroid-sparing effect, AU flares, adverse events, and so on; (study design) systematic literature reviews, randomized controlled trials, and observational studies. The study quality was assessed using the Jadad scale and according to The Oxford Centre for Evidence-based Medicine (update 2009). We included 13 studies of moderate-poor quality, with a mean duration from 5 months to 20 years, and number of AU patients ranging from 9 to 274. Patient's demographic and clinical characteristics were very heterogeneous. In most cases, uveitis anatomic classification criteria and outcomes definitions were unclear. Some of the studies only included AU patients with a systemic disease associated, mostly spondyloarthritis, others, mixed populations (idiopathic and systemic disease associated patients), and in some articles this data is not described. We found that methotrexate, cyclosporine A, azathioprine, adalimumab, and golimumab might prevent AU flares, improve ocular inflammation and visual acuity, and decrease systemic steroids doses. Although there is a lack of robust evidence, methotrexate, cyclosporine A, azathioprine, adalimumab, and golimumab might be effective in AU patients.
- 1 November 2015
- Published by Elsevier in Survey of Ophthalmology
- Vol. 60 (6) , 575-589
Anti–tumor necrosis factor-α therapy in uveitis
- 1 November 2015
- Published by Elsevier in Survey of Ophthalmology
- Vol. 60 (6) , 575-589
Anti–tumor necrosis factor-α therapy in uveitis
- 16 September 2015
- Published by Wiley in Tissue Antigens
- Vol. 86 (5) , 373-376
Study of association ofCTLA4gene variants to non-anterior uveitis
- 16 September 2015
- Published by Wiley in Tissue Antigens
- Vol. 86 (5) , 373-376
Study of association ofCTLA4gene variants to non-anterior uveitis
- 29 June 2015
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 14 (9) , 1353-1371
Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues
Management of patients with severe immune-mediated uveitis requires the use of immunosuppressive (IS) drugs in selected cases. This may be particularly challenging in certain patients with associated conditions, which may increase the risk of side effects or modify guidelines for the use of such drugs. Chronic viral and mycobacterial infections in the setting of non-infectious uveitis create a number of diagnostic but also therapeutic dilemmas to clinicians because they can be exacerbated by IS therapies with detrimental effects. In this review, we will focus on very specific chronic infections that can be affected by IS therapies: human immunodeficiency virus infection, chronic hepatitis virus infection and tuberculosis. The main aim of this review is to provide an updated and comprehensive practical guide for practitioners regarding the therapeutic decision-making and management of patients with non-infectious uveitis affected by the aforementioned infectious conditions. Clinicians should be aware of the risk of viral and mycobacterial reactivation of an underlying infection during IS therapy. However, most of these conditions do not represent an absolute contraindication if one were able to apply an appropriate prior screening and close monitoring of such therapy.
- 29 June 2015
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 14 (9) , 1353-1371
Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues
Management of patients with severe immune-mediated uveitis requires the use of immunosuppressive (IS) drugs in selected cases. This may be particularly challenging in certain patients with associated conditions, which may increase the risk of side effects or modify guidelines for the use of such drugs. Chronic viral and mycobacterial infections in the setting of non-infectious uveitis create a number of diagnostic but also therapeutic dilemmas to clinicians because they can be exacerbated by IS therapies with detrimental effects. In this review, we will focus on very specific chronic infections that can be affected by IS therapies: human immunodeficiency virus infection, chronic hepatitis virus infection and tuberculosis. The main aim of this review is to provide an updated and comprehensive practical guide for practitioners regarding the therapeutic decision-making and management of patients with non-infectious uveitis affected by the aforementioned infectious conditions. Clinicians should be aware of the risk of viral and mycobacterial reactivation of an underlying infection during IS therapy. However, most of these conditions do not represent an absolute contraindication if one were able to apply an appropriate prior screening and close monitoring of such therapy.
- 16 April 2015
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 14 (7) , 1071-1086
Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues
Management of patients with severe immune-mediated uveitis requires the use of immunosuppressive drugs in selected cases. This may be especially challenging in certain patients with concomitant conditions, which could increase the risk of side effects or modify guidelines for the use of such drugs. Therapeutic decision-making and management may be of particular difficulty in pregnancy as well as in patients with associated malignancies unrelated to a specific ophthalmic inflammatory condition. The main aim of this review is to provide an updated comprehensive practical guide for practitioners regarding the therapeutic decision-making and management of patients with severe immune-mediated uveitis in the context of pregnancy and malignancies. Management of patients with immune-mediated uveitis requiring immunosuppressive/immunomodulatory drugs might be particularly complicated by other conditions affecting their health and immune status. Clinicians should take into account such conditions, which might influence treatment response and the clinical outcome of these patients.
- 16 April 2015
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 14 (7) , 1071-1086
Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues
Management of patients with severe immune-mediated uveitis requires the use of immunosuppressive drugs in selected cases. This may be especially challenging in certain patients with concomitant conditions, which could increase the risk of side effects or modify guidelines for the use of such drugs. Therapeutic decision-making and management may be of particular difficulty in pregnancy as well as in patients with associated malignancies unrelated to a specific ophthalmic inflammatory condition. The main aim of this review is to provide an updated comprehensive practical guide for practitioners regarding the therapeutic decision-making and management of patients with severe immune-mediated uveitis in the context of pregnancy and malignancies. Management of patients with immune-mediated uveitis requiring immunosuppressive/immunomodulatory drugs might be particularly complicated by other conditions affecting their health and immune status. Clinicians should take into account such conditions, which might influence treatment response and the clinical outcome of these patients.